![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » ACAMBIS MVA SMALLPOX VACCINE IN US ITC PROBE AFTER BAVARIAN NORDIC COMPLAINT
ACAMBIS MVA SMALLPOX VACCINE IN US ITC PROBE AFTER BAVARIAN NORDIC COMPLAINT
September 21, 2005
Danish biopharmaceutical company Bavarian Nordic AS said the US International Trade Commission has started an investigation against Acambis PLC's MVA smallpox vaccine following a complaint of patent infringement by the Danish company. The complaint further alleges misappropriation of Bavarian Nordic's MVA-BN proprietary technology, it said.
Forbes (http://www.forbes.com/markets/feeds/afx/2005/09/21/afx2236033.html)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct